These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 8268536)

  • 1. Immunologic considerations in the use of cultured porcine hepatocytes as a hybrid artificial liver. Anti-porcine hepatocyte human serum.
    Takahashi M; Ishikura H; Takahashi C; Nakajima Y; Matsushita M; Matsue H; Sato K; Sato K; Noto H; Taguchi K
    ASAIO J; 1993; 39(3):M242-6. PubMed ID: 8268536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Metabolic evaluation of cultured porcine hepatocyte monolayers in human plasma from hepatic failure patients--basic study on development of a bioreactor in hybrid artificial liver].
    Matsue H
    Hokkaido Igaku Zasshi; 1996 Jul; 71(4):543-55. PubMed ID: 8809577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of immunologic reactions between cultured porcine hepatocytes and human sera.
    Hasegawa H; Shimada M; Gion T; Ijima H; Nakazawa K; Funatsu K; Sugimachi K
    ASAIO J; 1999; 45(5):392-6. PubMed ID: 10503613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of natural human anti-non-gal antibodies and their effect on activation of porcine gal-deficient endothelial cells.
    Saethre M; Baumann BC; Fung M; Seebach JD; Mollnes TE
    Transplantation; 2007 Jul; 84(2):244-50. PubMed ID: 17667817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human DAF on pig cells protects against human and non-human primate sera cytotoxicity mediated by exogenous or endogenous complement, as determined by flow cytometry.
    Díaz-Román TM; Mañez R; López-Pelaez E; Centeno A; Moscoso I; Pértegaz S; Doménech N
    Transpl Immunol; 2006 Aug; 16(2):125-30. PubMed ID: 16860716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of human xenoreactive antibodies in liver failure patients exposed to pig hepatocytes after bioartificial liver treatment: an ex vivo model of pig to human xenotransplantation.
    Baquerizo A; Mhoyan A; Kearns-Jonker M; Arnaout WS; Shackleton C; Busuttil RW; Demetriou AA; Cramer DV
    Transplantation; 1999 Jan; 67(1):5-18. PubMed ID: 9921790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flow cytometry complement-mediated cytotoxicity assay detects baboon xenoantibodies directed to porcine epitopes undetected by hemolytic assay.
    Diaz TM; Moscoso I; Centeno A; Lopez-Pelaez E; Ortega D; Doménech N
    Transpl Immunol; 2004 Dec; 13(4):313-7. PubMed ID: 15589745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterophile antibodies in the sera from renal transplant recipients.
    Akiyama N; Mori T; Kusaba R; Inou T; Kawamura A
    Jpn J Exp Med; 1978 Dec; 48(6):519-24. PubMed ID: 374802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The humoral immune response in humans following cross-perfusion of porcine organs.
    Cotterell AH; Collins BH; Parker W; Harland RC; Platt JL
    Transplantation; 1995 Oct; 60(8):861-8. PubMed ID: 7482748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of human fulminant hepatic failure sera on endogenous retroviral expression in pig hepatocytes.
    Nyberg SL; Hibbs JR; Hardin JA; Germer JJ; Platt JL; Paya CV; Wiesner RH
    Liver Transpl; 2000 Jan; 6(1):76-84. PubMed ID: 10648582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The serum level of xenoantibodies, and hDAF or alphaGAL expression on pig cells, modulate in vitro the protection given by hDAF to primate complement-mediated damage.
    Díaz TM; Mañez R; Moscoso I; López D; Santamarina I; Lopez E; Centeno A; Domenéch N
    Transplant Proc; 2005; 37(1):510-1. PubMed ID: 15808692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Membrane barrier of a porcine hepatocyte bioartificial liver.
    Nyberg SL; Yagi T; Matsushita T; Hardin J; Grande JP; Gibson LE; Platt JL
    Liver Transpl; 2003 Mar; 9(3):298-305. PubMed ID: 12619028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiological incompatibilities of porcine hepatocytes for clinical liver support.
    Schrem H; Kleine M; Borlak J; Klempnauer J
    Liver Transpl; 2006 Dec; 12(12):1832-40. PubMed ID: 17133583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bio-artificial liver from cultured human foetal hepatocytes: feasibility and prospects.
    Anand AC; Bhonde RR; Kurup S; Kochhar SP
    Trop Gastroenterol; 2000; 21(1):22-7. PubMed ID: 10835957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interspecies difference in liver-specific functions and biotransformation of testosterone of primary rat, porcine and human hepatocyte in an organotypical sandwich culture.
    Langsch A; Giri S; Acikgöz A; Jasmund I; Frericks B; Bader A
    Toxicol Lett; 2009 Aug; 188(3):173-9. PubMed ID: 19428196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of humoral cytotoxicity testing: the role of rabbit serum, xenoantibody, and human IgM.
    Quindlen EA; Wood WC; Kornblith PL
    J Immunol; 1977 May; 118(5):1836-42. PubMed ID: 858919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum antibodies against porphyric hepatocytes in patients with porphyria cutanea tarda and liver disease.
    Baravalle E; Prieto J
    Gastroenterology; 1983 Jun; 84(6):1483-91. PubMed ID: 6840477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IgM-enriched human introvenous immunoglobulin strongly inhibits complement-dependent porcine cell cytotoxicity mediated by human xenoreactive antibodies.
    Roos A; Rieben R; Faber-Krol MC; Daha MR
    Xenotransplantation; 2003 Nov; 10(6):596-605. PubMed ID: 14708528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of cirrhosis and liver failure in rats by hepatocyte xenotransplantation.
    Nagata H; Ito M; Cai J; Edge AS; Platt JL; Fox IJ
    Gastroenterology; 2003 Feb; 124(2):422-31. PubMed ID: 12557148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for Galalpha(1-3)Gal expression on primary porcine hepatocytes: implications for bioartificial liver systems.
    van de Kerkhove MP; Germans MR; Deurholt T; Hoekstra R; Joziasse DH; van Wijk AC; van Gulik TM; Chamuleau RA; Roos A
    J Hepatol; 2005 Apr; 42(4):541-7. PubMed ID: 15763340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.